Treatment of Intermediate Stage Hepatocellular Carcinoma: a Review of Intrahepatic Doxorubicin Drug-Delivery Systems.

The biopharmaceutical properties of doxorubicin delivered via two drug-delivery systems (DDSs) for the palliative treatment of unresectable hepatocellular carcinoma were reviewed with relation to the associated liver and tumor (patho) physiology. These two DDSs, doxorubicin emulsified with Lipiodol (R) and doxorubicin loaded into DC Bead (R) are different regarding tumor delivery, release rate, local bioavailability, if and how they can be given repeatedly, biodegradability, length of embolization and safety profile. There have been few direct head-to-head comparisons of these DDSs, and in-depth investigations into their in vitro and in vivo performance is warranted.